Vertex Pharmaceuticals Inc
SWB:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
SWB:VX1
|
US |
|
CompuGroup Medical SE & Co KgaA
F:COP
|
DE |
|
A
|
Apple Inc
XHAM:APC
|
US |
|
Ateme SA
F:AYD
|
FR |
|
Fujikura Ltd
F:FJK
|
JP |
|
W
|
Wolters Kluwer NV
XMUN:WOSB
|
NL |
Wall St Price Targets
VX1 Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for VX1 is 486.39 EUR with a low forecast of 289.04 EUR and a high forecast of 583.68 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is VX1's stock price target?
Price Target
486.39
EUR
According to Wall Street analysts, the average 1-year price target for VX1 is 486.39 EUR with a low forecast of 289.04 EUR and a high forecast of 583.68 EUR.
What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 3 years is 10%.
What is the Gross Profit forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
11%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 3 years is 11%.
What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 3 years is 17%.
What is the Pre-Tax Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
20%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 47%. The projected CAGR for the next 3 years is 20%.
What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
18%
The compound annual growth rate for Net Income over the next 3 years is 18%.
